Nat cell biology:先天性心脏病致病原因有新解

2014-09-24 孙国根 医学论坛网

讯 复旦大学生命科学学院和遗传工程国家重点实验室钟涛教授领衔的研究团队经多年潜心研究,近日在心脏发育和细胞纤毛生物学领域获得进展,他们发现前列腺素信号通路能够调控细胞纤毛生长和心脏左右不对称发育,该研究不仅揭示了在胚胎形成和器官发育过程中前列腺素信号的重要性,而且有助于解密先天性心脏病和人类其他疾病的细胞分子病因。相关成果已在线发表在国际著名细胞生物学杂志《自然•细胞生物学》上,引起世界同行关

复旦大学生命科学学院和遗传工程国家重点实验室钟涛教授领衔的研究团队经多年潜心研究,近日在心脏发育和细胞纤毛生物学领域获得进展,他们发现前列腺素信号通路能够调控细胞纤毛生长和心脏左右不对称发育,该研究不仅揭示了在胚胎形成和器官发育过程中前列腺素信号的重要性,而且有助于解密先天性心脏病和人类其他疾病的细胞分子病因。相关成果已在线发表在国际著名细胞生物学杂志《自然•细胞生物学》上,引起世界同行关注。

据悉,前列腺素是一种具有多种生理作用的活性物质,能够参与机体的炎症反应、血管平滑肌舒张和收缩、肿瘤发展等多种生理和病理过程;而纤毛是以细胞微管为主体伸向细胞外能运动的突起物,它广泛分布于人体多种组织和器官的上皮细胞表面。纤毛不仅参与了早期发育过程中胚胎与器官的不对称性发育,还参与了调控人体重要的生理功能及细胞内重要信号通路的转导,如纤毛生长发育异常就会引起人类先天性心脏病、多囊肾、男性不育、纤毛不动综合征等多种相关疾病。

钟涛教授课题组首次把前列腺素信号通路与纤毛生长及器官发育相联系,以斑马鱼和人类细胞为模型,通过分析斑马鱼遗传突变体“leakytail”,发现一种叫“LKT”的转运蛋白如果缺失,就会造成心脏和其他内脏器官随机性偏侧等异常表型,而他们的研究证明这些“异常表型”主要是因为胚胎发育时期细胞表面纤毛生长“有缺陷”引起的。钟涛研究团队进一步研究发现:LKT转运蛋白具有在细胞内到细胞外“转运”前列腺素的特殊本领,而前列腺素通过结合定位于纤毛膜上的G蛋白偶联受体,进而影响纤毛内转运蛋白的正向速度,并最终调节纤毛生长和心脏左右不对称发育。

《自然•细胞生物学》专家认为,上述成果可能最终为心脏疾病诊疗策略的转化应用开辟新思路,带来新希望。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1766898, encodeId=6b061e668988c, content=<a href='/topic/show?id=64f5343e2f' target=_blank style='color:#2F92EE;'>#Biol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3437, encryptionId=64f5343e2f, topicName=Biol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=446937890434, createdName=12498ebem31暂无昵称, createdTime=Mon Apr 06 20:33:00 CST 2015, time=2015-04-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1917075, encodeId=bbea191e0758a, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Sat Dec 20 21:33:00 CST 2014, time=2014-12-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1880285, encodeId=f350188028520, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sat Jun 13 03:33:00 CST 2015, time=2015-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1959150, encodeId=750e1959150a3, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Thu Oct 30 04:33:00 CST 2014, time=2014-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1868905, encodeId=051e1868905eb, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Tue Feb 10 22:33:00 CST 2015, time=2015-02-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1369192, encodeId=f9dd1369192b4, content=<a href='/topic/show?id=bc9f28589d0' target=_blank style='color:#2F92EE;'>#先天性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28589, encryptionId=bc9f28589d0, topicName=先天性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a435298, createdName=huirong, createdTime=Fri Sep 26 01:33:00 CST 2014, time=2014-09-26, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1766898, encodeId=6b061e668988c, content=<a href='/topic/show?id=64f5343e2f' target=_blank style='color:#2F92EE;'>#Biol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3437, encryptionId=64f5343e2f, topicName=Biol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=446937890434, createdName=12498ebem31暂无昵称, createdTime=Mon Apr 06 20:33:00 CST 2015, time=2015-04-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1917075, encodeId=bbea191e0758a, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Sat Dec 20 21:33:00 CST 2014, time=2014-12-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1880285, encodeId=f350188028520, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sat Jun 13 03:33:00 CST 2015, time=2015-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1959150, encodeId=750e1959150a3, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Thu Oct 30 04:33:00 CST 2014, time=2014-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1868905, encodeId=051e1868905eb, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Tue Feb 10 22:33:00 CST 2015, time=2015-02-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1369192, encodeId=f9dd1369192b4, content=<a href='/topic/show?id=bc9f28589d0' target=_blank style='color:#2F92EE;'>#先天性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28589, encryptionId=bc9f28589d0, topicName=先天性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a435298, createdName=huirong, createdTime=Fri Sep 26 01:33:00 CST 2014, time=2014-09-26, status=1, ipAttribution=)]
    2014-12-20 sunylz
  3. [GetPortalCommentsPageByObjectIdResponse(id=1766898, encodeId=6b061e668988c, content=<a href='/topic/show?id=64f5343e2f' target=_blank style='color:#2F92EE;'>#Biol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3437, encryptionId=64f5343e2f, topicName=Biol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=446937890434, createdName=12498ebem31暂无昵称, createdTime=Mon Apr 06 20:33:00 CST 2015, time=2015-04-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1917075, encodeId=bbea191e0758a, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Sat Dec 20 21:33:00 CST 2014, time=2014-12-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1880285, encodeId=f350188028520, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sat Jun 13 03:33:00 CST 2015, time=2015-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1959150, encodeId=750e1959150a3, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Thu Oct 30 04:33:00 CST 2014, time=2014-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1868905, encodeId=051e1868905eb, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Tue Feb 10 22:33:00 CST 2015, time=2015-02-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1369192, encodeId=f9dd1369192b4, content=<a href='/topic/show?id=bc9f28589d0' target=_blank style='color:#2F92EE;'>#先天性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28589, encryptionId=bc9f28589d0, topicName=先天性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a435298, createdName=huirong, createdTime=Fri Sep 26 01:33:00 CST 2014, time=2014-09-26, status=1, ipAttribution=)]
    2015-06-13 liye789132251
  4. [GetPortalCommentsPageByObjectIdResponse(id=1766898, encodeId=6b061e668988c, content=<a href='/topic/show?id=64f5343e2f' target=_blank style='color:#2F92EE;'>#Biol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3437, encryptionId=64f5343e2f, topicName=Biol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=446937890434, createdName=12498ebem31暂无昵称, createdTime=Mon Apr 06 20:33:00 CST 2015, time=2015-04-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1917075, encodeId=bbea191e0758a, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Sat Dec 20 21:33:00 CST 2014, time=2014-12-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1880285, encodeId=f350188028520, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sat Jun 13 03:33:00 CST 2015, time=2015-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1959150, encodeId=750e1959150a3, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Thu Oct 30 04:33:00 CST 2014, time=2014-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1868905, encodeId=051e1868905eb, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Tue Feb 10 22:33:00 CST 2015, time=2015-02-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1369192, encodeId=f9dd1369192b4, content=<a href='/topic/show?id=bc9f28589d0' target=_blank style='color:#2F92EE;'>#先天性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28589, encryptionId=bc9f28589d0, topicName=先天性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a435298, createdName=huirong, createdTime=Fri Sep 26 01:33:00 CST 2014, time=2014-09-26, status=1, ipAttribution=)]
    2014-10-30 维他命
  5. [GetPortalCommentsPageByObjectIdResponse(id=1766898, encodeId=6b061e668988c, content=<a href='/topic/show?id=64f5343e2f' target=_blank style='color:#2F92EE;'>#Biol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3437, encryptionId=64f5343e2f, topicName=Biol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=446937890434, createdName=12498ebem31暂无昵称, createdTime=Mon Apr 06 20:33:00 CST 2015, time=2015-04-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1917075, encodeId=bbea191e0758a, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Sat Dec 20 21:33:00 CST 2014, time=2014-12-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1880285, encodeId=f350188028520, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sat Jun 13 03:33:00 CST 2015, time=2015-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1959150, encodeId=750e1959150a3, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Thu Oct 30 04:33:00 CST 2014, time=2014-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1868905, encodeId=051e1868905eb, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Tue Feb 10 22:33:00 CST 2015, time=2015-02-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1369192, encodeId=f9dd1369192b4, content=<a href='/topic/show?id=bc9f28589d0' target=_blank style='color:#2F92EE;'>#先天性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28589, encryptionId=bc9f28589d0, topicName=先天性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a435298, createdName=huirong, createdTime=Fri Sep 26 01:33:00 CST 2014, time=2014-09-26, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1766898, encodeId=6b061e668988c, content=<a href='/topic/show?id=64f5343e2f' target=_blank style='color:#2F92EE;'>#Biol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3437, encryptionId=64f5343e2f, topicName=Biol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=446937890434, createdName=12498ebem31暂无昵称, createdTime=Mon Apr 06 20:33:00 CST 2015, time=2015-04-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1917075, encodeId=bbea191e0758a, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Sat Dec 20 21:33:00 CST 2014, time=2014-12-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1880285, encodeId=f350188028520, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sat Jun 13 03:33:00 CST 2015, time=2015-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1959150, encodeId=750e1959150a3, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Thu Oct 30 04:33:00 CST 2014, time=2014-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1868905, encodeId=051e1868905eb, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Tue Feb 10 22:33:00 CST 2015, time=2015-02-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1369192, encodeId=f9dd1369192b4, content=<a href='/topic/show?id=bc9f28589d0' target=_blank style='color:#2F92EE;'>#先天性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28589, encryptionId=bc9f28589d0, topicName=先天性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a435298, createdName=huirong, createdTime=Fri Sep 26 01:33:00 CST 2014, time=2014-09-26, status=1, ipAttribution=)]
    2014-09-26 huirong

相关资讯

Lancet:脉搏血氧饱和度监测联合临床评估适用于中国新生儿先天性心脏病筛查

由复旦大学附属儿科医院心内科专家黄国英教授、贾兵教授执导的一项前瞻性研究表明,在中国,脉搏血氧饱和度监测联合临床评估用于检查新生儿先天性心脏病是可行、可靠的。该研究成果发表于2014年4月23日的 The Lancet。研究人员对上海的三家医院进行了初步研究,评估脉搏血氧饱和度监测联合临床评估筛查先天性心脏病的准确性。在征集新病例前,研究人员制定了数据收集计划,随后进行了一项大型的、前瞻性的、多中

Int J Cardio:波生坦可治疗唐氏综合征患者的先天性心脏病相关肺动脉高压

口服波生坦对先天性心脏病(CHD)相关的肺动脉高压(PAH)治疗有效,但对唐氏综合征患者的疗效仍然未知。那不勒斯第二大学心血管学院的Michele D’Alto等人对此进行了研究,发现波生坦对于患有唐氏综合征的CHD相关PAH患者同样有效,研究结果发表于《国际心脏病学杂志》。 本次研究的对象为有无唐氏综合征的CHD相关PAH患者,旨在评估波生坦在这两类患者中的长期疗效。对患者基线水平和波生坦治疗

Am J Cardiol:先心病患者宜用仅含孕酮成分的避孕药

  西班牙一项研究表明,尽管一些患者有禁忌证,但有相当高比例的先天性心脏病(CHD)患者曾应用雌激素孕酮复合避孕药(EPCC),在转至孕前门诊前,CHD患者应用孕酮成分避孕药(PC)比例较低。PC无血栓形成副作用,并且妇产科副作用发生率可接受,值得推广。论文于5月24日在线发表于《美国心脏病学杂志》(Am J Cardiol)。   既往报道显示,CHD患者避孕方法包括EPC

JACC:先心病成年患者NT-proBNP水平与其心功能有关

研究要点:1.研究人员进行了此项研究,旨在评估NT-proBNP对于先心病患者的临床意义,并评估NT-proBNP与先心病患者心脏功能及运动功能之间的关系。2.研究结果显示,NT-proBNP水平因先心病的种类不同而有差异,其中Fontan术后的先心病患者NT-proBNP水平最高,主动脉缩窄患者NT-proBNP水平最低。3.NT-proBNP与患者的超声心动图参数及运动耐力具有相关性。此前有研

NEJM:二叶主动脉瓣临床综述

二叶主动脉瓣(BAV)是成人先天性心脏病中最常见的类型之一,发生率约为1.3%。相比其他先天性心脏病其致死率和并发症发生率较高。虽然主动脉瓣狭窄和反流是BAV最常见的并发症,然而主动脉根至主动脉弓近端的任何或所有部位的扩张在这些患者中大约占50%。现有证据显示BAV患者主动脉扩张的形式多变,这可能表明在分子机制、血液流变学及临床特征方面存在异质性。鉴于此,来自加拿大多伦多大学圣米高医院心脏外科

EHJ:王红艳等发现MTR基因多态性与先天性心脏病有关

2013年6月,国际著名杂志《欧洲心脏杂志》(European Heart Journal,影响因子14.1)在线发表了复旦大学生命科学学院王红艳课题组的研究论文“Genetic variants reducing MTR gene expression increase risk of congenital heart disease in Han Chinese population”(Zha